Kurma Partners has closed its fourth and largest fund, raising €215 million to pursue disruptive therapeutic solutions. The firm’s new vehicle signals continued investor appetite for early- to mid-stage platform bets that can scale into later clinical development. Kurma pointed to prior exits including acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma as evidence of its ability to support value creation. The close adds another sizeable European life-sciences fund to a market that has seen growing allocation toward venture-backed biotechs. For founders and portfolio companies, a fresh fund close often translates into improved fundraising options for additional rounds, including bridge financing for clinical milestones and follow-on support for platform maturation. The deal also fits into a broader pattern of concentrated capital targeting therapeutic areas where mechanistic differentiation, biomarker strategies, and translational execution can support differentiated outcomes.